Ann: Initial Dosing Completed in Cohort 1 of RP11 MAD Study, page-9

yeah, it’s definitely good news. It was worrying me if they continued treatment on the SAD patients outside the trial and there was an adverse event that there would be a reaction from the FDA. Apparently they don’t like adverse events happening outside of the trial environment and can be a bit punitive. Now they are inside a trial I am pretty happy. And they can be counted for the safety and efficacy data.

I'm still hoping for some efficacy data in the next week or two. I remember Rohan saying in one of his presentations that if they had more patients show a response they would push the FDA for a faster timeline. An announcement like that with a good double whammy would definitely bring a smile.

I love the way this company keeps pushing to improve their timelines. I also like this the PYC hot copper threads just quietly. Everyone is very respectful of each others views.